<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04644393</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_1086</org_study_id>
    <nct_id>NCT04644393</nct_id>
  </id_info>
  <brief_title>Responsiveness and Validation Study of MFM-20 in SMA Patients Treated With Nusinersen</brief_title>
  <acronym>RetroNusiMFM</acronym>
  <official_title>Responsiveness and Validation Study of MFM-20 in SMA Patients Treated With Nusinersen: Retro NusiMFM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Motor Function Measure (MFM), a reliable tool assessing motor function and its&#xD;
      progression in most neuromuscular diseases, is widely used in France in many teams. It can be&#xD;
      used regardless of the severity of the motor impairment or the ambulatory status of the&#xD;
      patient, allowing its use throughout the whole follow-up period of the patient, even in case&#xD;
      of the loss of walking. Two versions of the MFM exist, one composed of 32 items validated for&#xD;
      patients from 6 years old (MFM-32) and a shorter version composed of 20 items validated for&#xD;
      patients between 2 and 6 years old (MFM-20).&#xD;
&#xD;
      In order to show the possible use of MFM-20 as early as the age of 2 years to validly and&#xD;
      reliably monitor the evolution of the motor function of children treated with Nusinersen, we&#xD;
      propose in this project to study the sensitivity to treatment-induced change of MFM-20 and&#xD;
      the validity of the scale in this population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MFM-20 responsiveness</measure>
    <time_frame>At least 6 Months after the first MFM-20 assessment, and at maximum 24 months</time_frame>
    <description>The MFM-20 sensitivity to change indexes considered will be the effect amplitude and the Standardized Response Mean (SRM).</description>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Spinal Muscular Atrophy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        -  Boys and girls with Type 1 or 2 Spinal Muscular Atrophy, genetically confirmed&#xD;
&#xD;
          -  Aged 2 to 6 years old&#xD;
&#xD;
          -  Treated by Nusinersen for at least two months&#xD;
&#xD;
          -  With at least 3 MFM-20 repeated measures, and with adelay minimum between the first&#xD;
             and the last MFM-20 of 6 months&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Boys and girls with Type 1 or 2 Spinal Muscular Atrophy, genetically confirmed&#xD;
&#xD;
          -  Aged 2 to 6 years old&#xD;
&#xD;
          -  Treated by Nusinersen for at least two months&#xD;
&#xD;
          -  With at least 3 MFM-20 repeated measures, and with adelay minimum between the first&#xD;
             and the last MFM-20 of 6 months&#xD;
&#xD;
          -  With parental assent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Patients with associated cognitive impairment making impossible evaluation of motor&#xD;
             function&#xD;
&#xD;
          -  Patients participating to a clinical study with a potential effect on their motor&#xD;
             function.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laure LE GOFF, MD</last_name>
    <phone>+33 4 72 12 95 04</phone>
    <email>laure.le-goff@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pascal Ripeprt, RCA</last_name>
    <phone>+33 4 27 85 63 08</phone>
    <email>pascal.rippert@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de neuropédiatrie et neurochirurgie de l'enfant Centre de Référence maladies neuromusculaires AOC CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Julien DURIGNEUX, MD</last_name>
      <phone>02 41 35 44 45</phone>
      <email>judurigneux@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de génétique médicale Pôle de Pédiatrie CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Catherine SARRET, MD</last_name>
      <phone>04.73.75.06.53;</phone>
      <email>csarret@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie et réanimation pédiatriques CHU Paris IdF Ouest - Hôpital Raymond Poincaré</name>
      <address>
        <city>Garche</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Susana QUIJANO-ROY, MD</last_name>
      <phone>01.47.41.78.90;</phone>
      <email>susana.quijano-y@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon, Hôpital Femme Mère Enfant</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laure LE GOFF, MD</last_name>
      <phone>+33 4 72 12 95 04</phone>
      <email>laure.le-goff@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Laure LE GOFF, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Apf Esean</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Capucine de LATTRE, MD</last_name>
      <phone>02 40 34 76 74</phone>
      <email>c.delattre@esean.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut I-Motion - Centre de recherche pédiatrique en pathologies neuromusculaires CHU Paris Est - Hôpital d'Enfants Armand-Trousseau</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Andreea SEFERIAN, MD</last_name>
      <phone>01 44 73 65 37</phone>
      <email>a.seferian@institut-myologie.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de pédiatrie CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gaelle Gousse, MD</last_name>
      <phone>04 77 82 87 29</phone>
      <email>gaelle.gousse@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unité de Neurologie Pédiatrique Centre de Référence Maladies NeuroMusculaires Hôpital des Enfants CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Claude CANCES, MD</last_name>
      <phone>05.34.55.85.77;</phone>
      <email>cances.c@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 20, 2020</study_first_submitted>
  <study_first_submitted_qc>November 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>November 20, 2020</last_update_submitted>
  <last_update_submitted_qc>November 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spinal Muscular Atrophy</keyword>
  <keyword>Motor Function Measure</keyword>
  <keyword>Outcome Assessment</keyword>
  <keyword>Nusinersen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

